The results demonstrate the safety and efficacy of Fasenra in the treatment of acute eosinophilic exacerbations in asthma and ...

Expert Rev Gastroenterol Hepatol. 2012;6(5):591-601. Limited research has been developed on the molecular basis of EGE and its pathophysiology is poorly known, with most of the available ...

Every 30 seconds, someone in the world will experience a flare-up of their asthma or chronic obstructive pulmonary disease ...

Eosinophilic esophagitis (EoE) is a chronic esophageal inflammatory disease of undetermined pathophysiology that results in dense mucosal eosinophilia and esophageal dysfunction. In childhood ...

Eosinophilic fasciitis (EF) is a rare subacute fibrosing disorder of unknown aetiology, characterised by thickening of the muscular fascia and subcutaneous tissue, leading to swelling of limbs and ...

Benralizumab, a monoclonal antibody, is the first breakthrough in asthma and COPD flare-up treatment in 50 years. Targeting ...

The publication of this infographic was sponsored by ADVENT, a non-promotional medical education program designed to advance ...

The first new treatment for asthma attacks in 50 years may be a “game-changer”, researchers say. Offering patients an ...

Benralizumab is a monoclonal antibody that targets specific white blood cells, called eosinophils, to reduce lung ...

Injection for asthma and COPD attacks shows a 30% reduction in the need for further treatment, outperforming steroid tablets.

Benralizamab is a monoclonal antibody which targets specific white blood cells, called eosinophils, to reduce lung ...

An injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, ...